You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
恆瑞醫藥(01276.HK)藥物獲中國批准進行聯合臨床試驗
阿思達克 06-05 17:20
恆瑞醫藥(01276.HK)公布,集團與子公司蘇州盛迪亞生物醫藥、上海盛迪醫藥,收到國家藥品監督管理局核准簽發關於注射用SHR-A1811、阿得貝利單抗注射液、蘋果酸法米替尼膠囊的《藥物臨床試驗核准通知書》,將於近期進行臨床試驗。 試驗批准注射用SHR-A1811聯合抗腫瘤藥物治療實體瘤的開放、多中心Ⅰb/Ⅱ期臨床研究。 公司注射用SHR-A1811(注射瑞康曲妥珠單抗)已於今年5月獲批上市,適用於治療存在HER2(ERBB2)活化突變且先前接受過至少一種系統治療的不可切除的局部晚期或轉移性非小細胞肺癌(NSCLC)成人患者。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account